ICAP Celebrates 15 years

Improving the health of individuals, families, and communities around the world.

In 2003—out of the crisis of the global HIV epidemic—ICAP emerged. Propelled by the vision of founding director Wafaa El-Sadr, MD, MPH, MPA (pictured), a Columbia Mailman professor of Epidemiology, ICAP endeavors to strengthen the health systems of under-resourced communities around the world, demonstrating how innovative solutions can be implemented and scaled up to bring health and hope to those hardest hit by HIV/AIDS, as well as such devastating diseases as malaria and tuberculosis. Through a mix of research, implementation, and training, ICAP pursues its mission to make health and well-being a reality for populations around the world.

HIV In the 30 years since the pandemic began, nearly 30 million lives have been lost to HIV. Today, an estimated 35 million people worldwide are living with the virus. Each year, an additional 2.7 million people, including 390,000 children, are newly infected. Through service, research, education, training, and impact measurement, ICAP works with host countries and other partners to support efforts to confront HIV around the world.

MALARIA Malaria remains a major health threat, particularly in sub-Saharan Africa and among children and pregnant women, worldwide. To promote accurate diagnosis and optimize treatment, ICAP has trained more than 2,500 laboratory professionals to conduct more accurate microscopy diagnoses and provided clinical training to more than 2,400 healthcare workers.

TUBERCULOSIS TB accounts for nearly one-quarter of HIV-related deaths; in some sub-Saharan countries, more than half of those with active TB are co-infected with HIV. ICAP promotes synergies between national TB and HIV control programs and supports the development of complementary clinical programs. ICAP also promotes clinician training, improved pediatric care and treatment, enhanced diagnosis, and development of best practices.
**IMPACT MEASUREMENT** Through the Population-based HIV Impact Assessment (PHIA) project, ICAP has partnered with the U.S. Centers for Disease Control and Prevention and ministries of health in 14 countries to collect critical information on the status of HIV epidemics at the national level since 2014. This information provides a report card on progress thus far in confronting the epidemic while informing strategic planning to guide future action.

**PREVENTION** In the United States, ICAP is evaluating new methods and approaches to HIV prevention. Currently ICAP is doing pioneering research in Harlem and the Bronx on long-acting pre-exposure prophylaxis (PrEP) to reduce HIV transmission.

**EDUCATION & TRAINING** Professional development of a global health workforce features prominently in ICAP’s mission. The Global Nurse Capacity Building Program, for example, has helped to add more than 13,000 nurses and midwives throughout sub-Saharan Africa. More than 5,500 healthcare workers have participated in ICAP-supported training and networks, which include mentorship programs, as well as distance learning opportunities.

**ICAP’S GLOBAL PRESENCE**

- Projects in **33** countries
- **1,650** clinicians, researchers, data scientists, and operations, financial, technical, and communications advisers supporting more than . . .
- **5,300** health facilities around the world

**ICAP’S IMPACT**

- **29M** people have been tested for HIV
- **2.3M** people have been enrolled in HIV care
- **1.3M** people have begun HIV treatment
- **616K** women have received treatment to prevent HIV transmission to their babies
- **4.2M** people have been screened for TB